“With granted patents in the US, Japan and the EU, we will, in the major markets, have the patent rights for a potential new screening method to diagnose cancer at its early stages. The newly established, dedicated subsidiary will allow easier communication and transparency around the synthetic antibody patents and our core business”, comments Patrik Eschricht, PHI CEO.

Synthetic antibodies

The patent family protects technology for creating synthetic plastic antibodies that can be tailored to recognize and bind to specific molecules with high precision, such as identifying cancer cells in blood or tissue samples.

The synthetic antibodies were developed within the GlycoImaging project. PHI holds the commercial rights to the innovation, owning 75 % of the patents, while Germany’s federal institute for materials research owns the remaining 25 %.

This disclosure contains information that Phase Holographic is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 21-03-2023 10:00 CET.

For additional information, please contact:
Lisa Bodily
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis

Phase Holographic Imaging (PHI) develops instrumentation and software for time-lapse cytometry. The products are used for long-term quantitative analysis of the dynamics of live cells, particularly significant in the research of cancer, as well as in the treatment of inflammatory and autoimmune diseases. The products are sold globally through the company's distributors. The company is based in Lund, Sweden, and in Boston, Massachusetts.